Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.0
A day after Prime Medicines emerged from semi-stealth with new CRISPR tech that made even venture capitalist Bob Nelsen say “holy crap,” a Cambridge, MA-based company with similar ambitions in the works is beefing up its executive suite — starting with former BeiGene CFO Howard Liang.
Tessera Therapeutics has tapped Liang as its first CFO, in addition to several other new hires including Mana Therapeutics vet Madhusudan Peshwa as CTO for cell therapy; Avrobio alum Bill Querbes as senior VP of therapeutic discovery and translational sciences; and insitro’s former head of functional genomics Cecilia Cotta-Ramusino as senior VP of platform development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.